Definitive Contract 75N91023C00060

Triton Systems, Inc., a small business based in Chelmsford, Massachusetts, received a $3.19 million Small Business Technology Transfer (STTR) Phase II contract award from the National Institutes of Health on September 30, 2023, to develop Digital SatioRx, a remotely controllable, disposable microneedle transdermal drug delivery device capable of delivering any liquid FDA-approved transdermal drug at very low cost. The contract, which is designated as a total small business set-aside, falls under the Advanced Research Projects Agency for Health's Microneedle Transdermal Drug Delivery Device Topic 02 and is structured as a firm fixed-price definitive contract with a completion date of January 14, 2026. Work will be performed at the company's facility in Chelmsford, Massachusetts.

This award builds on ARPA-H's strategic initiative to advance innovative medical technologies that address critical healthcare needs. The microneedle-based drug delivery patch represents a disruptive technology with significant potential for commercialization, aligning with ARPA-H's mission to accelerate the development of transformative health solutions. Triton Systems' extensive experience in medical device development, demonstrated through prior federal awards in advanced medical technologies and product commercialization, positions the company well to deliver this innovative transdermal delivery solution that could improve patient outcomes and expand treatment options for various pharmaceuticals.